Compare GGR & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGR | PMN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | Taiwan | Canada |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 84.1M |
| IPO Year | 2021 | 2022 |
| Metric | GGR | PMN |
|---|---|---|
| Price | $2.82 | $3.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $42.27 |
| AVG Volume (30 Days) | 7.3K | ★ 362.7K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.97 | N/A |
| Revenue Next Year | $6.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $0.29 |
| 52 Week High | $5.43 | $27.40 |
| Indicator | GGR | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 31.77 |
| Support Level | $2.51 | $2.78 |
| Resistance Level | $3.32 | $15.05 |
| Average True Range (ATR) | 0.14 | 1.21 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 18.07 | 10.75 |
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.